Moreover, our in vivo studies on kidney histone proteins reveal a significant drop in GSDMD‐NT and IL‐6 expressions post‐stevioside administration, making this study a pioneering effort in establishing stevioside as a therapeutic agent for AKI via GSDMD pathway inhibition. This evidence concerns the gene GSDMD and acute kidney injury.